Congestive heart failureis thefinal common pathway for many diseases that affect the myocardium (Table  1 ) (1) . Different clinical conditions predominatei n different parts of the world. Whilst coronary artery disease accounts for morethan 65% of cases in North America and Europe, other problems assume greater significance for populations with shorter life expectancy in Africa, Asia or South America. In the Italian SEOSI study,7 0% of patients had previous myocardial infarction whereas 15% had hypertensive heart disease. Idiopathic dilatedcardiomyopathy and valvular heart disease together accounted for the remaining 15% (2) . Less well understood is the fact that virtually half of heart failurepatients have well preserved left ventricular ejectionfraction (LVEF). From a 15-year experience of heart failure admissions to the Mayo clinic, Owan et al showed 47% of patients to havep reserved leftv entriculars ystolic function (LVEF >50%, mean 61%) (3) . Moreover the diastolic dysfunction group had asimilarly dismal prognosis with 29% mortality in 1y ear and 65% by 5y ears. Clearly LVEF aloneisapoor predictor of clinical disability and survival.
Systolic heart failureresults from adverse remodelling of the left ventricle in response to as timulus (myocardial infarction, virus, toxin etc). The term left ventricular remodelling describes thecardiovascular compensatory mechanism for an acute loss in myocardial contractile function (4) . Heart failures ymptoms stem from 2main pathophysiological processes, which can be addressed surgically irrespective of the cause. Raised left ventricular end diastolicp ressure (LVEDP) and impaired filling properties cause pulmonary congestion andb reathlessness, whilst decreased systemic blood flow triggers the vascular, cytokine and humeral responses which cause salt and water retention and fatigue (5) . In systolic heart fail-ure a rise in LVEDP causes the ventricle to dilate to a mores pherical shape. Initially this process proves beneficial through the Frank-Starlingmechanism because the enlarged chamber maintains stroke volume even though LVEF falls. Soon dilatation has ap rogressively detrimentale ffect becauseo fi ncreased wall tension and impaired sub-endocardial blood flow.
Heart failurep rogressioni sc haracterised by changes in the morphologyofthe myocyte (enlargement), altered genetic expression to fetal type,a nd bioenergetic decline with impaired forced generation (6) . Disruption of thecollagen matrix decreases force transmission whilst cardiac dyssynchrony results in force wasting. Ve ntricular dilatation eventually causes mitral regurgitation through altered left ventricular geometry, papillary muscle dysfunction and annular dilatation. Progressive volume overload contributes to left ventricular enlargement and worsening mitral regurgitation with decreased survival. Increased chamber sphericity and the onset of mitral regurgitation arei mportant markerso fp oor prognosis with one-year mortality between 54-70% (7) .
The failing heart beats at morethan 120,000 times per day pumping moret han 6,000 litres of blood against an increased systemic and pulmonary afterload. As wall tension increases so does myocardial energy and oxygen consumption. At an advanced stagethe therapeutic benefit of drug treatment or cardiac resynchronisation therapy is limited. The potential for symptomatic relief depends upon as ubstantial increase in cardiac output and reduction in LVEDP.
THE RELATIONSHIP bETWEEN LEFT VENTRICULAR SIzE AND PROgNOSIS
For patients with coronary arterydiseasethe relationship between myocardial infarct size and prognosis is clearly defined (8) . If moret han 20% of the ventricularc ircumference is dyskinetic or akinetic, the remainingc avity dilates to preserve stroke volume. When moret han 40% of the myocardial circumference is impaired, the normal left ventricular end sys-tolic volumeindex (LVESVI) of 25 ml/m 2 increases to >60ml/m 2 and elevated wall tensioncauses progressive left ventricular failure. After thrombolysis, coronary reperfusion and epicardial salvage may not improvecontractility if endocardial necrosis causes scar formation. Hypertrophy of non-ischaemic segments is acompensatory mechanism for elevated wall stress but increasesthe potential for dysrhythmia. Myocyte hypertrophy causes prolongation of the action potential and alterations in key sarcolemal channels and currents that contribute to action potential repolarisation (9) . This may allow early depolarisation and create are-entry circuit.
Heart failurepatients without reversible ischaemia or with LVESVI >100 ml/m 2 do not have improved outlook with revascularisation alonea nd coronary artery bypass surgery carries substantial mortality risk. Nevertheless the now historic CASS Registry showed 5-yearsurvival for patients with LVEF <25% was 41% with medical treatment but 62% with CAbg (10) .Thisprovided clear evidence that surgery could influence the natural history of ischaemic heart failure. The benefit of revascularisation was an improvement in the contractilityo fs tunned or hibernating myocardiumin60-70% of cases as long as the LVESVI remained below 100 ml/m 2 .Acritical mass of reversiblyi schaemic myocardiumm ust be present to achieve global improvement in LV function. No wall motion recovery occurs followingr evascularisation when morethan 50% of myocardial wall thicknesses comprised of scar tissue (11) .
In practice ischaemic cardiomyopathy is aheterogeneous condition whereac ombination of myocardial scar,h ibernation and stunning all result in impairment of left ventricular systolic function (12) . The workload of myocardium remote from theakinetic or dyskinetic areas is increased by the dysfunctional changes. Increased wall stress causes lengthening and thinning of the LV wall through lateral slippage of myocardial tissue planes. Changes in ventricular geometry,wall tension and filling pressures contribute to the increased metabolic requirements of non-isch-aemic myocardium. Abnormalities of diastolic function also occur during stress in most patients with extensive coronary disease. Thesea re manifest by reduced peak left ventricular filling rate and increased time to peak filling rate. Hypoxia impairs relaxation of the papillary muscles during early diastole becauset his is an active energy dependent process.
During stress or ischaemic episodes, abnormalities of systolic and diastolic LV function may be sufficientlyseveretofurther elevate LVEDP causing dyspnoea as well as angina. Some patients have increased LVEDP at rest withc onsiderably reducede xercise capacityb ut only mildly increased cardiac chamber size. Thesepatients often have severeischaemicdysfunction in non-scarred parts of the ventricles and may be helpedb yr evascularisation. Others have moderateo rs everec ardiomegaly,r educed cardiac index and elevation of right atrial pressurewith hepatomegaly and fluid retention. This latter group usually has extensive myocardial scarring, and LVESVI >150 ml/m 2 and areu nlikely to be improved by revascularisation alone. Myocardial ischaemia, left ventriculars hape and volume and mitral regurgitation are3i mportant targets for surgical treatmenti np atients with ischaemic cardiomyopathy (13). Whilst donor heartsc an be supplied only to am inority of heart failure patients, other surgical options can provide symptomatic relief for the majority.The revolution in functional cardiac imagingb y3 -dimensional echocardiography, magneticr esonance or contrast enhanced computerised tomography has provided a much better understanding of the surgical anatomy and pathophysiology of heart failure to supportd evelopments in non-transplant heart failuresurgery.
Left ventricular volume also has an important bearing upon outcome in surgery for idiopathic dilated cardiomyopathy (IDCM). Ve ntricular restoration surgery and mitral valve repair can be combined in IDCM patientsu sing the septal anterior ventricular exclusion (SAVE) procedure ( 14) . The myocardial fibrosis and impaired contraction in IDCM arenot uni- formly distributed in the ventricle as once throught. Experience with partial left ventriculectomy (the batista operation) demonstrated agreater degree of interstitialfi brosis in the septum comparedw ith the lateral wall. One reason for failureofthe batista approach was that the most contractile part of the ventricle (in the circumflex territory) was excised during reduction of chamber size (15) . Yanagidaa nd coworkers also showed heterogeneity of wall motion in IDCM with aless contractile septum than posteroinferior wall (16) . Suma showed left ventricular size to be an important risk factor in IDCM and suggested that left ventricular volumereduction in combination with mitral repair may improve prognosis for those with greatly enlarged hearts. The group targeted volume reduction surgery on the akinetic septum by using al ong narrow patch to provide ar enewed ellipsoid shape to the ventricle (17) .
THE ROLE OF SURgERYINISCHAEMIC CARDIOMYOPATHY
Heart failures urgery for systolic dysfunction addresses the 3V 's: ventricle, valve and vessels. Combined surgical ventricular restoration (SVR) together with mitral valve repair and myocardial revascularisation already provides outcomes equivalent or better than cardiac transplantation ( Fig. 1) .
For ischaemic cardiomyopathy patients with adilated ventricle (LVESVI >100 ml/m 2 ), arecent study from O'Neil and colleagues at the Cleveland Clinic emphasises that SVR is clearly the most important component of the3V's (18) . Twohundred and twenty heart failurep atients underwent SVR of which 80% had concomitant CAbg and 49% mitral valve repair. Sixty per cent of these patientswereNYHA III or IV with mean LVEF 21.5 ±7.3% and mean LVEDD 6.4 ± 1.0 cm. Thirty-day mortality was only 1% with 3-and 5-year survivals of 90% and 80% respectively.Atfollow up 85% of patients wereN YHA Io rI I. Post-operative left ventricular volume was the principle determinant of functional recovery during late follow up. LVESVI was reduced from amean value of 120 ± 46 ml/m 2 to 77 ±26m l/m 2 though the rise in LVEF was modest: (21.5% to 24.7%, p<0.01). These results ares ubstantially better than those presented by gillinov for combined CAbg and mitral valve repair in ischaemic cardiomyopathy,w here5 -year survival was only 55% for this relatively high risk population (19) .O'Neil and colleagues concluded that outcomes were substantially better than committalt oat ransplant waiting list.
The concept that ag lobular ischaemic cardiomyopathy ventricle can be surgically restored to an elliptical shape with improved function is largely attributable to Vincent Dor (20) . Dor's endoventricular circular patch-plasty followed earlier attempts at physiological reconstruction by Jatene and Cooley (Fig. 2 ). Dor's contribution was to remove endocardial scar,e xclude akinetic septum and restoret he curvatureofthe anterolateralwall. Myocardial revas- cularisation and correction of mitral regurgitation complete the package. In the event of spontaneous or inducible ventricular tachycardia, cryotherapy was applied to the edges of the resection (50% of cases).
Between developing the surgical principles in 1984 and 2002, the Dor group operated on 1,050 patients (21) . They werepredominantly NYHA III or IV with LVEF <35%, LVESVI > 50 ml/m 2 , LVEDVI > 100 ml/ m 2 and mean pulmonary arterial pressure>25 mm Hg. One thirdo ft he cases underwent mitral valve repair.T he mean improvement in LVEF in Dor's series was between 10% to 15%. Overallhospital mortality was 7.52%,but this fell to 4.8% between 1998 to 2002. Diastolic filling improved and ventricular arrhythmias werec ontrolled immediately in 90% of cases. Late survival exceeded 50% at 10 years rivalling transplantation though many patients weret oo old or unsuitable for this option.
SVR in combination with coronary revascularisation and mitral repair has been widely adopted as the strategy of choice for ischaemic cardiomyopathy.The RESTORE group Registry contains over 12,000 patients with an overall3 0-day mortality of 5% (22) . Mean LVESVI for these patients was reduced from 80 ±51ml/m 2 down to 57 ±34ml/m 2 providing an increase in mean LVEF from 29.6 ±1 1% to 39 ±1 2.3%. Five-year survival was 70%. Using pressurev olume loops beforea nd after SVR, Tulner and colleagues showed acute volume reduction with shape alteration and decrease in ventricular dyssynchrony (23) . All parametres of systolic function werei mproved but therew as some increase in diastolic stiffness. Although SVR improved the mechanical efficiency of ventricular contraction, stroke work remained constant.T his contrasts with patients who undergo mi-tral annuloplasty alone whereonly small changes in systolicfunction areobserved.Astripand colleagues used am athematical model to study the differential effectsofSVR on end systolicand enddiastolicfunction (24) . This showedl eft ventricular mechanical synchrony to be substantially improved with beneficial effects for dyskinetic segments but less marked improvement for akinetic scar.W hen compromised but contracting muscle wasresected as for the batista operation,t herew as an overall negative effect on pump function.
THE ROLE OF REVASCULARISATION IN HEART FAILURE
Revascularisation does not improve the function of scar tissue. Nor is it possible on the basis of echocardiography,c oronary angiography or ventriculography to determine which segments of the myocardium might benefit from improved perfusion. Forh eart failurepatients without limiting angina, early studies showed CAbg to be associated with poor short-term outcome and ap erioperative mortality rate of 15-20%. Yoshida and gould demonstrated that patients with LVEF <43% after myocardial infarction, had a 3-year mortality rate of 38% in contrast to only 6% when LVEF exceeded 43% (8) . However,L VEF alone was ap oor predictor of mortality in the presence of hibernating myocardium. Viable muscle was an independent predictor of survival and ar eliable marker for those who werel ikely to benefit from CABG. Three-year mortality rate for patients with LVEF <43% and no viable myocardium was 63% in contrast to 13% for those with viable myocardium treated by revascularisation. For patients with only scar in the territorya tr isk from coronary occlusion, a3 -year mortality rate of 50% was no different with or without revascularisation. CABGthereforehas no benefit in this subgroup. They may nevertheless gain improvement from VRS to provide the morefavourable elliptical shape. In this context Yamaguchi first published 54% 5-year survival with CAbg alone for ischaemic cardiomyopathy but followed this 7y ears later with 90% 5-year survival for similar patients when SVR and CAbg werecombined (25, 26) .
The goal of myocardial viabilitya ssessment is to prospectively identify reversibly ischaemic territory with the potential for functional improvement in patients whose prognosis might be improved by ahigh risk CAbg operation. Viability testing is indicated in heart failure patients with suspected coronary disease or dilated cardiomyopathy,who arebeing considered for cardiac transplantation (27) . Also in those with known coronary disease and severel eft ventricular dysfunction who have breathlessness but little angina. Viabilitytesting is redundant in patients with unstable angina, postinfarction angina or chronic stable angina because revascularisation is indicated for relief of the symptoms.
For ischaemic heart failurep atients with minimal angina, the combination of good target vessels and morethan 25% myocardial viability, suggests the likelihood of benefit from CABG. In those with less than 25% viability, poor target vessels or in reoperative candidates, surgery is unlikely to provide benefit. The advantages of myocardial viabilityt esting were demonstrated by Haas in as eries of patients with severe3 -vessel disease and LVEF <35% (28) . Half wereoperated on based upon angiographic findings alone. The others weree valuated by positron emission tomography and selectedo nt he basis of hibernating segments and favourable target vessels. The hibernating myocardium group had alower hospital mortality rate( 0% versus 11.4%,p=0.04), al ower incidence of postoperative complications (33% versus 67%, p=0.05) and fewer patients with low cardiac output syndrome (3% versus 17%, p=0.05). Furthermoret he 1-year survival rate was better (97 ±8 % versus 79 ±, p=<0.01). The LVEF increased from 26% to 35% in those with myocardial viability but was unchangedi nt hosew ithout. This and supporting evidence indicated that myocardial viability assessment allowed better definition of both the risk and benefit of revascularisation in ischaemic cardiomyopathy patientsaswell as allowing refinement of selection in potential transplant candidates. Ultimately functional magnetic resonance imagingf or assessment of left ventricular wall motion and scar thickness (using gadolinium) provides clear evidence of the potential for wall motion improvement versus the need for restoration surgery.Magnetic resonance imaging also allows assessment of the cause and degree of mitral regurgitation.
Allmana nd colleagues performed ac omprehensive meta analysis of largely retrospective data on myocardial viability studies (29) . In 24 reports of patient survival after viability testing, annual mortality rates werea nalysed to produce ar isk adjusted rela-tionship between the severity of LV dysfunction, presenceofmyocardial viability,and survival benefit associated with revascularisation. The report included 3,088 patients with LVEF 32 ±8%followed for 25 ±1 0m onths. For those with stunned or hibernating myocardium, revascularisation was associated with aremarkable 79.6% reduction in the annual mortality rate (16% versus 3.2%, p=<0.0001) compared with medical treatment. In contrast, patients without viability had intermediate mortality tending to higher rates with CAbg versus medical therapy (7.7% versus 6.2%). Patients with viability showed adirect relationship between the severity of LV dysfunction and magnitude of benefit with revascularisation. Importantly no benefit was obtained by revascularisation in patients without viability at any level of LVEF. The perioperative mortality ratesw erei mpressively high in patients without viability (around 10%) but negligiblei nt hose with viability.T his difference in mortality is curious given the time frame of improvement in wall motion following revascularisation.
bach and colleagues prospectively studied patients with ischaemic cardiomyopathy using preoperative assessment of regional perfusion, glucoseu se and contractile function (30) . Of the dysfunctional segments 22% wereidentified as stunned, 23% werehibernating and 55% werescar tissue. In stunnedmyocardium, contractile function improved significantly at 3m onths but without further improvement at 14 months. Notably 30% of stunned segments did not improve. In hibernating segments 31% had improved by 3m onths and 61% had recovered fully by 14 months. Histopathologic studiesinischaemic cardiomyopathy indicateap rogressivei ncrease in ultrastructurald amage and myocardial fibrosis as the ischaemic process ranges from stunning, to hibernation, thennon-transmural scar and full thickness scar. Clearly most non-transmural and all full thickness scar will never improve in function following revascularisation. In Haas' study only 31% of stunnedsegments and 18% of hibernating segmentsr esponded by complete functional recovery over 1-year postoperatively.F ailuret oi mprove was associated with mores evered egenerative changes in the myocyte including depletion of sarcomeres, accumulation of glycogen, loss of sarcoplasmic reticulum and cellular sequestration.U sing gadolinium-enhanced contrast MRI, Kim and colleagues showed that 78% of dysfunctional segments shown to have full thickness viability,s howed improvement in contractility after revascularisation, but 90% of segments with 50-75% of wall thickness scar did not improve (11) .
SURgERYFOR IDIOPATHIC DILATED CARDIOMYOPATHY
In idiopathic dilated cardiomyopathy,t he LV cavity dimensions enlarge, wall tension increases and impaired contractility is further complicated by functional mitral regurgitation. batista pioneered left ventricularv olume reduction using radical partial left ventriculectomy (15) . Thisaimed to reduce wall stress and myocardial oxygen requirement through the La-Place principle. batista's compelling presentations usingb ovine ands nake hearts led to widespread adoption of the procedurei nt he absence of verified outcome data. In early reports virtually all NYHA Class IIIorIVpatients with LVEDD >7 cm werecandidates for the operation. Awedge of muscle in the circumflex marginal territory was resected between and sometimes includingt he papillary muscles, extending from the apex of the heart up to 2c mf rom the mitral annulus.M oret han 80% of patients required mitral valve surgery because papillary muscle reorientation caused redundancy of the chordae and valve prolapse. Batista used the Alfieri technique of joining the mid portionofthe anterior and posterior mitral leaflets. The reported hospital mortality ranged from 1.9% to 27% with an average of 17.4% (31) . Causes of death included persistent or progressive congestive heart failure, bleeding, stroke and ventriculard ysrhythmia. Postoperativelyt herew as a significant decrease in both LVEDVI and LVESVI. In ac arefully selected Cleveland Clinic population LVEDD reduced from 8.4 ±cmt o5 .92 ±0.8 cm (p = 0.01) and the LVEDVI reduced from 133 ±48.6 ml to 64.1 ±26ml(p= <0.0001). LVEF increased from 16 ± 7.6% to 31.5 ±10.9% (p =<0.0001) (32) . Nevertheless the improvement in LV systolicf unction was offset by an early reduction in compliance then progressive ventricular redilatation.
The only reliable late information came from the Cleveland Clinic where62patients underwent partial left ventriculectomy between 1996 and 1998 (32) . Virtually half received an implantable defibrillator and 18% required an LVAD as rescue therapy.T his kept hospital mortality down to 2p atients. Survival was 80% and 60% at 1year and 3years respectively.This included 3p atients who died after transplantation and 32 patients who returned to NYHA Class IV congestive heart failure. Freedom from Class IV heart failurewas 81%, 57% and 42% at 30 days, 1year and 3y ears respectively. Event-free survivalw as only 26% at 3y ears. Unpredictability and poor medium term results led to the abandonment of the batista operation.
In contrast, the SAVE procedured eveloped by Suma addresses the fibrotic dysfunctionalpart of the ventricle and provides morepredictable results (17) . This operation (developed for Japanese patients who do not have access to cardiac transplantation), was reported in 36 NYHA Class III/IV patients, mean age 60 years and with morethan 2+ mitral regurgitation. All had LVEDD >77mmand an akinetic septum. In addition to theSAV Eprocedure, 26 had mitralrepair and 10 mitral replacement. Sixteen also had tricuspid repair.O perative mortality was 13.8%, but 60% of those needingu rgent operation died. Nevertheless 1-and3 -year survival was 67.5% and 60.7% respectivelyand survivors wereNYHA IorII. Therewas a marked improvement in left ventricular volume and function. LVEF improved from 20.9 ±6.4 to 27.5 ± 8.8% whilst LVEDP fell from 24.3 ±9.7 mm Hg to 19.4 ±7.6 mm Hg. Mean LVESVI was reduced from 181.3 ±55.4 ml/m 2 to 133±54.1 ml/m 2 .E ven at 3y ears therew as no significant redilatation of the ventricle. Once again postoperative left ventricular volume was the strongest determinant for late survival. This was 67% in those with LVESVI <150 ml/ m 2 and only 42% with LVESVI >150 ml/m 2 .This suggests that IDCM patients with larger ventricles might be better treated by long-termc irculatory support with an LVAD.
MITRAL REPAIR AS AN ISOLATED PROCEDURE IN IDCM
One-year mortality for dilated cardiomyopathy patients with LVEF <25% and moderate to severemitral regurgitation ranges between 50% and 70%. Mitral regurgitation develops in the presenceofastructurally normal valve through dilatation of the annulus, altered ventricular geometry and restricted leaflet motion. Leaflet coaptation fails with acentral regurgitant jet. In the presenceofmitral regurgitation virtually all measures of systolic functioni ncluding LVEF tend to overestimateL Vp erformance. In congestive heart failurem itral valve replacement with excision of the subvalvar apparatus results in prohibitive mortality.D ivision of the chordae tendoni results in marked elongation of the LV accompanied by as ubstantial reduction in maximal LV systolic elastance (33) . by contrast the preservation of chordal, annularand subvalvarcontinuity maintains the geometric relationships of the LV cavity and promotes improvement in LVEF when volume overload is corrected. bolling has shown that dilated cardiomyopathy patients with poor LV function (LVEF <25%) can be managed by mitralvalverepair alonewith acceptable mortality and morbidity (34) . bolling's patients had NYHA Class III or IV heart failuredespite maximum medical treatment and preoperative LVEF ranging from 8% to 25% (mean 16% ±3%). All patients undergo mitral annuloplasty using an undersized remodellingr ing and virtually half have concomitant tricuspid annuloplasty.P ostoperatively most patients return to NYHA Class Io rI Iw ith a mean LVEF of 26% for the group. Functional capacity improved substantially withar ise in MVO2 from 14.5 ml to 18.5 ml O 2 /kg/min. Actuarial 1-and 2-year survival was 82% and 72%r espectively withl ate echocardiographic datashowing amarked reduction in LV sphericity,regurgitant volume and regurgitant fraction.
Ve ntricular volume is an important denominator of outcome after mitral repair in IDCM. Horii and colleagues examinedthe relationship between LVES-VI and functional recovery in 55 IDCM patients undergoing mitral repair or replacement, 38 of whom also required tricuspid valve surgery (14) . These patients had amean age of 55 years andwereall NYHA III or IV.Half werealready on inotropic support. Preoperative LVESVI ranged from 70 to 270 ml/m 2 .They werea rbitrarily divided into 2g roups with LVESVI above or below 150 ml/m 2 .The small ventricle group had mean LVESVI of 114±26ml/m 2 whilst the large ventricle group had LVESVI of 183 ±36ml/m 2 .Hospitalm ortalityw as 4.3% for electives urgery and 14.5% for those on inotropes. In the smaller ventricle group there was an improvement in LVEF from 24.6% to 30.4%a nd ac oncomitant fall in LVESVI from a mean of 114ml/m 2 to 99 ml/m 2 at 1year.Incontrast the large LV group with LVESVI> 150 ml/m 2 or LVEDD >70 mm, had no significant benefitfrommitral repair.This partially explains the variable results of mitral repair alone in other IDCM series (35) . The question as to whether external ventricular constraint could add additional benefittomitral repair was addressed by the Acorn ClinicalT rial (36) . This was a randomised study of NYHA III/IV patients with LVEF <35% (mean 23 ±9%) who received mitral repair with or without the restraining Acorn polyester mesh. In short, external restraintp rovided no additional benefit above mitral repair alone.
In summary,l eft ventricular volume is an important determinant of outcome after non-transplant surgery for heart failure. Ve ntricular restoration surgery providest he key to improvement in left ventriculars ystolic function, which can be further enhanced by revascularisation of stunned or hibernating myocardium and elimination of mitral regurgitation.
MAXIMISINgSURVIVAL POTENTIAL IN VERY HIgH RISK HEARTF AILURE SURgERY
The mean age and risk profile of patients referred for cardiacsurgery is constantly increasing. Elevated risk profile translates into increased hospital mortality. Coronary artery bypass patients with heart failure and significant co-morbidity have mortality rates exceeding 10% (37) . Acollective review of 279 dialysis dependent coronary bypass patients reported 12.2% hospital mortality (38) . The Mayo Clinic reported 21% perioperative mortality after aortic valve replacement for patients with LVEF <35% and borderline transvalvular gradient. Intraoperative myocardial injury is prevalent in the increasingly elderly surgical population because the myocardium is less tolerant to ischaemia with increasing age (40) .
Patients who aredifficult to wean from cardiopulmonary bypass and those who subsequentlydeteriorate into al ow cardiac output state have mortality rates between 50-80% (41). In establishedcardiogenic shock, conventional treatmentw ith inotropes, the intra-aortic balloon pump (IAbP) or temporary circulatory support devices do not substantially improve survival. Efforts to improve surgical results ared ependent upon myocardial protection and preservation of contractile function in the postoperative period. The mechanisms of postischaemia function are well defined. After cardiac surgery myocardial stunning impairs contractile function for several days despite normal or near-normal coronary blood flow and oxygen supply (42) . Stunning causes transient systolic and diastolic dysfunction but with the potential for full recovery.The underlying pathophysiology is less efficient oxygen utilisation by the contractile apparatus (43) . This results from impaired calcium handlingb yt he sarcoplasmic reticulum and reduced calcium sensitivity of the contractile proteins. Myocardial oxygen consumption for excitation-contraction coupling is inappropriately high with adecrease in contractile efficiency.The calcium sensitivity of the myofilaments is also decreased in stunned myocardium resultingi nm echano-energetic mismatch and impaired systolic and diastolic relaxation (44) . The beta-adrenergic receptor system plays an important role in regulatingcalcium homeostasis and mediating positive myocardial inotropic effects via adenelate cyclase. Althoughi notropic support improves contractile functioni ns tunned myocardium the effects of prolonged inotropy may be damaging.beta-adrenergic agents improve cardiac output at the expense of increased myocardial oxygen consumption. Whilst systolicf unction and blood pressurei mprove, diastolic dysfunction persistsa nd may deteriorate further.Inotropes increase stroke work independent of MVO2causing an energy demand in excess of that required by the contractile apparatus (45) . The oxygen wasting effect impedes myocardial recovery. Continued exposuretohigh levels of catecholamines during the development of myocardial dysfunction leads to chronic beta-adrenergic desensitisation (46) . This results in decreased effectiveness of beta-adrenergic receptorstimulating inotropic agents in the failing heart. Thus patients with poor left ventricular function already have fewer functional beta-adrenergic receptors andl ess responsiveness to inotropic agents. Adecline in beta-adrenergic receptor function and receptor densitya lso occurs in patients with idiopathic dilated cardiomyopathy (47) .
Coronary and valve patients with very poor ventricular function often have the most to gain from successful surgery.T his is also the group at greatest risk from postischaemic myocardial dysfunction. because risk scoring systems provide insufficient weight to very poor ventricular function, some patients may be declined surgery on the groundsofelevated risk. From as eries of several thousand coronary bypass patients, the Toronto Hospital Group identified 9independentp redictors of postoperative low cardiac output syndrome (48) . These werel eft ventricular ejection fraction <20%, repeat operation, emergency operation, female gender, diabetes, age >70 years, left main coronary arteryd isease, recent myocardial infarction and triple vessel disease. Poor left ventricular function is the most importantindex of mortality because these patients have less margin for recovery from postoperative stunning. The overall incidence of low cardiac output syndrome was 9.1% with ahospital mortality of 16.9% versus 0.9% (p <0.001) for those with an uncomplicated postoperative course. Low cardiac outputpatients weremorelikely to have had aperioperative myocardial infarction (14.3% versus 1.8%, p<0.001). The prevalence of low cardiac output syndrome was 8.1% after complete revascularisation versus 14.6% for others (p <0.001).
THE MANAgEMENT OF PATIENTS AT RISK FROM LOW CARDIAC OUTPUT SYNDROME
Three categories of patient area ts ubstantial risk. First aret hose who present urgently for surgery already in cardiogenic shock often with the complication of myocardial infarction or infected endocarditis (49) . Second is the group submitted for high-risk non-transplant heart failuresurgery with LVEF <20% together with renal impairment or aortoiliac disease, which precludes the use of an IAbP (50) . The third categoryi ncludes patients who sustain an unanticipated negative event during surgery,w hich may prejudice separation from cardiopulmonary bypass.
Postcardiotomy support begins with inotropic drugs thoughp rolonged use may augment perioperative ischaemic injury.Inotropes increase stroke work, left ventricular wall tension and myocardial oxygen consumption, thus depleting energy reserves. High doses may cause endocardial necrosis and impaired diastolic function. because of this an IAbP or circulatory support system arepreferable for patients with moderate or severehemodynamic compromise. The principle effects of the IAbP aret or educe left ventricular afterload (and MVO2), improve diastolic coronary blood flow and thereby enhance subendocardial perfusion in patients with elevated left ventriculare nd diastolic pressure( LVEDP) (51) . The IAbP itself does not substantially increase systemic blood flow.Peak diastolic coronary flow velocity increases by amean of 117% with an increase in mean flow velocity integral of 87%. The IABP also has the capacitytoimprove right heart function through ventricular interdependencemechanisms and augmentation of right coronary blood flow. between 10% to 15% of patients undergoing cardiac surgery,n ow receive an IAbP either preoperatively to reduce risk or postoperatively afterweaning difficulties (52) .Preoperative IABP placement allows stabilisation of patients with acute coronary syndromes beforerevascularisation. In one series of coronary artery bypass patients with ejection fraction <25%, 30 day mortality with preoperative IAbP placement was 2.7% compared with 11.9% for unsupported patients (53) . In alarge series of IAbP patients from the Massachusetts general Hospital multivariant predictors of death in medical and surgical patients included IAbP insertion in the operating room or intensive careu nit, transthoracic insertion, advanced age, procedures other than coronary artery bypass grafting and insertion for cardiogenic shock (54) . In this series predictors of deathweregreat age, mitral valve replacement, prolonged CPb, urgent or emergency operation, preoperative renal dysfunction, complex ventricular dysrhythmias, right ventricular failureand emergency resumptionofCPb.Fromthe benchmark Registry and Society of Thoracic Surgeons (USA) National Databases, IAbP procedures were initiated preoperatively in 52.4% and 63.5% respectively of all IAbP use (55, 56) . Preoperative insertion was associated with am ortalityo f1 8.8 to 19.6%, intraoperative insertion 27.6 to 32.3% and postoperative insertion 39% to 40.5%.P re-emptive use of the IAbP appears to provide an absolute risk reduction in mortality of around 7%.
WHICH PATIENTS ACHIEVEMOST bENEFIT FROM ELECTIVE IAbP USE?
The literature suggests that hospital mortality rate for coronary bypass patients with LVEF <25% ranges from 4.8% to 14.3% (27) . Wechsler showed that poor LVEF,advanced age, presence of mitral regurgitation and left main coronary disease werer isk factors for hospital mortality in coronary bypass patients (57) . Dietl showed LVEF <25%, redo CAbg, NYHA Class III or IV,left main coronary disease, urgent or emergency CAbg and LVEDP >20mmHgtobeindicators of increased hospital mortality (53) . With the growth of percutaneous coronary interventions these elevated risk characteristicsa re becoming moref requent in the surgical setting.
INDICATIONS AND PATIENT SELECTION FOR MECHANICAL CIRCULATORY SUPPORT
Awide variety of temporary and long-term mechanical support devices aren ow availablei na ffluent healthcaresystems.blood pumps resuscitateaneverincreasing number of heart failurepatients by LVAD or bIVAD support with or withouta ccess to cardiac transplantation. The goal of postcardiotomy circulatory support is to restorenormalhemodynamicsand oxygen delivery in patientswherethe native heart is temporarily is unable to sustain this function despite IAbP and inotropic support. Accepted criteria for circulatorysupport in cardiogenic shock include acardiaci ndex <2.0 l/min/m 2 ,s ystolic bloodp ressure <90m mH g, pulmonary capillary wedge pressure >20m mH g, with biochemical evidence of poor tissue perfusion (58) . Patient is usually oliguric and acidotic with cool extremities and obtunded mental state. In the face of maximum supportive treatment theseare indices of impending death. Only one third of patientsw ill recover irrespective of mechanical circulatory support. Thisindicates thatthe traditional guidelines for LVAD or bIVAD deployment should be revised to promote earlier intervention now that safer moreuser-friendly devices areemerging.
Patient selection is crucial in determining as uccessful outcome. The presence of irreversible renal, hepatic or respiratory failurer emains an absolute contraindicationt oi nitiating support. Established stroke and sepsis arerelativecontraindications. Data from the International Society of Heart and Lung Transplantation Registry indicate that patients older than 70 years of age have decreased survival after circulatory support though weaning is not affected by age (59) . Risk stratification models show the need for mechanical ventilation, urine output <30m l/ hour,p reoperative central venous pressure>16 mm Hg, hepatic dysfunction (prothrombin time >16seconds), an increasing serum creatinine and bilirubin levels to be adverse prognostic factors.
Thereare currently two groups of patients in whom temporary supporti sb eneficial. The first comprises those patients who sustain reversible myocardial injury with ar easonable expectation of myocardial recovery and device removal in less than two weeks. As well as postcardiotomy failuret his group includes patients with acute myocardial infarction an viral myocarditis. Extracorporeal pulsatile and nonpulsatile VA DS and extracorporeal membrane oxygenation areu sed in these patients (Fig.3 ) . The sec-ond group aret hose in whom recovery is unlikely and who requireb ridge to cardiac transplantation. both limited duration extracorporeals ystemsa nd implantable LVADs ared eployed in the bridge to transplant setting. In addition to these conventional approaches,long term bridge to myocardial recovery in chronic heart failurea nd short term bridge to a long term implantable LVAD aree mergingi ndications for circulatory support ( 60) . The timing of initiation of postcardiotomy support has ap rofound effect on outcome. Early deployment based on predictive models provides improved rates of weaning and survival to hospital discharge (61) . Delay increased the need for biventricular support,w hich is associated with decreased survival. As the severity of cardiogenic shock and organ dysfunction increase, so does the need for biventricular support.Ase pisode of cardiac arrest prior to support decreases survival from around 47% to 7%. If ap atient is weaned from CPb on two high dose inotropes, the hospital mortality is around 42%. This increases to 80% if three high dose inotropes arer equired. If VA Dinsertion occurs within 3hours of the first attempt to wean from CPB then 60% can be separated from VA Ds upport with 43% hospital discharge rate. This contrasts with only 27% VA D separation and 7% hospital discharge when VA Dinsertion is delayed for morethan 3hours after weaning from CPb. In the Abiomed Registry 63% of cases werepostcardiotomy patientswith an average age of 56 years and am ean duration of 5d ays support (62) . Fifty two per cent of patients had biventriculara ssist,3 4% left ventricular assist and 14% isolated right ventricular assist. Postcardiotomy support resulted in 30% survival when the pumps were inserted within 3h ours of the decision to implant, survival was 60% versus 20% when insertion was delayed.
Pae and colleagues from the Pennsylvania State University reviewed combined registry data on the use of first generation temporary circulatory support devices between 1985 and 1990 (63) . Nine hundred and sixty five patients weret reated for postcardiotomy shock of which 45% wereweaned from the system and 25% discharged from hospital. Notably 90% of patientsw ho survived to leave hospital were weaned from the pump within one week. Those requiring uni-ventricular support alone faired better irrespective of whether pulsatile pneumatic or nonpulsatile centrifugal pumps wereu sed. Patient age >70years was the principle determinant of mortality. Irrespective of multiple complications including bleeding, stroke and renal failure, those who left hospital had 2-year actuarial survival of 82% and 86%, and werei nN YHA Class Io rI I. golding and colleagues from the Cleveland Clinic reported a12-year experience of 91 patients supported with ac entrifugal blood pump after failuretowean from CPb (64) . Mean age of postcardiotomy patients was 54.8 years and mean duration of support 3.56 days (range 1 hour to 19 days). Sixty two per cent of the patients weres uccessfully weaned but only 25% survived to leave hospital. Bleeding occurred in 87% with an astonishing mean transfusion requirementof53units. Renal failureoccurred in 47%, cerebral vascular accident in 13%, thromboembolism in 13% and hepatic insufficiency in 13%. In the follow-up period one thirdofpatients died but most of the remainder were in NYHA ClassIo rI I. Patientsw ith biventricular failureand renal failurehad worse late outcomes.
ELECTIVE TRANSFER FROM CARDIO-PULMONARYbYPASS TO CENTRIFUgAL bLOOD PUMP SUPPORTINVERYHIgH RISK CARDIAC SURgERY
The decision to pre-emptively deploy an LVAD must balancesafety with efficacy.Inorder to improve outcome in borderline survival situations following high risk cardiac surgery,W estaby and colleagues decided to wean directly from CPbtothe Levitronix Centrimag system (65) . This systemisdesigned to reduce bleeding and thromboembolic complications ( Fig. 4 ). It is reliable and versatile so that it can be quickly implemented in situations of rapid deterioration. For elective transferf romC Pb to centrifugal blood pump support the patients at highest risk of postcardiotomy cardiogenicshock areselected beforesurgery.L VA D implantation is undertaken during 30 minutes of reperfusion time beforediscontinuation of CPb. Conduits for theinflowand outflowcannulas areused to improve the safety of decannulation. The system is filled during reperfusion and deairing of the native heart. The patient is then weaned directly from CPb onto LVAD flow to provide between 3and 4litres per minute.Antegrade cardiac ejection continues to provide systemic pulsatility.Combined output from the device and the native left ventricle is around 3.0 L/ min/m 2 .For recovery after ischaemic arrest the support duration is less than 7d ays. In this time frame the Levitronix pump is reliable, safe and effective (66) . It is readily managed by nursing staff and easily portable. Reoperation for bleeding and decannulation problems area voided by theu se of conduits. With av iew to explant,m yocardial functioni sa ssessed daily with the pump flow turneddown to 2.0 L/min/m 2 .A fter sustainable improvement in myocardial function has been achieved the patient is re-turned to the operating room, the pump is switched offa nd the cannulas arew ithdrawn. As part of the step-down process an IAbP may be employed for a further 24-48 hours.This electivecirculatory support stragety has been used very successfullyi nas mall series of patients with coronary and aorticvalve disease all with LVEF <15%. All patients with chronic heart failures urvived. To date therea re moret han 300 patients in the Levitronix pump registry of whom 45% of cases have been for postcardiotomy salvage with amean duration of 9days and 53% survival. It is likely that the 47% mortality could have been reduced substantially by anticipatingp ostoperative deterioration and using the blood pumpelectively to prevent cardiogenic shock during the duration of reversible postischaemic stunning.
The function of LVADs is dependento nt ranspulmonary blood flow and filling of the prosthetic ventricle. LVAD flow may be compromised if increased pulmonary vascular resistance (PVR) limits the ability of the right ventricle to pump through the lungs. The pulmonary vasodilating action of inhaled nitric oxide has been effectively used in heart failurep atients to optimise LVAD filling and systemicfl ow (67) . Intravenous drugs including sodium nitroprusside, nitroglycerine, phosphodiesterase inhibitors and prostaglandin E1 also dilate the pulmonary vasculatureb ut cause hypotension in the systemic circula- tion. Hypotension may then impair coronary perfusion pressurea nd precipitate right ventricular ischaemia. Inhaled nitric oxide is as elective pulmonary vasodilator which stimulates guanylate cyclase to generate cyclic guanosine 3', 5'-monophosphate (cgMP),i nt urn CgMP activates protein kinaseg which lowers intracellular calcium causing vascular smooth muscle relaxation (68) . As nitric oxide defuses through the vascular smooth muscle cell and into blood it is immediately bound to haemoglobin and inactivated. In surgical patients whose pulmonary hypertension fails to respond to inhaledn itric oxide, the effectiveness can be increased by preventing the breakdown of CgMP by inhibiting phosphodiesterase with dipyridamole (69) .
In LVAD patients randomly allocated to receive nitric oxide(20 ppm) or anitrogen gas placebo, mean pulmonary artery pressureimmediately fell from 35 ± 6m mH gt o2 4±mm Hg in those receiving nitric oxide (67) . This resulted in an increased LVAD flow from 1.9 ±0.2 to 2.7 ±0.3 L/min/m 2 .N itrogen gas had no effect on hemodynamics.When crossed over from nitrogen gas to nitric oxide, control patients responded in as imilar way.All patients werew eaned from nitric oxide within 7days when LVAD support becamesufficient. Taking all of these factors into consideration, nitrico xide gas has an important role in cardiac surgery and should be made available in all units who undertake heart failuresurgery (70) .
THE EXPANDINg ROLE OF LONg-TERM CIRCULATORY SUPPORTTECHNOLOgY
What can be done for those withoutasurgical target or recoverablemyocardium? Currently thereare two established options: cardiac transplantation or lifetime mechanical circulatory support (71) . Athirdpossibility is that of cellulartherapy and myocardial tissue engineering.This may be supported by mechanical left ventricular unloading to reduce LVEDP and promote myocardial blood flow in an attempt to sustain the transplanted cells.Cardiac transplantation is largely restricted to patients under 65 years of age (72) . Though contemporary survival exceeds 80% at one year and almost 50% at 10 years, the process is still beset with complications of rejection, coronary vasculopathyand malignancy through the immunosuppressive regime (72) . by the very natureo fh eart failure, 80% of patients areolder than 65 years, whilst younger patientsoften have co-morbidity such as renal impairment or diabetes, which preclude them from transplantation. In contrast the prospects for lifetime mechanical circulatory support arec ontinuously improving. blood pump bioengineering has developed rapidly in recentyears and thereare many new LVADs undergoing bench, animal or clinical testing (73) . Much smaller continuous flow devices have been developed with bloodw ashed microceramicb earings,e lectromagnetic suspension, and now hydrodynamic suspensiontoprovide durability and minimal thrombogenicity (Fig. 5 ). The power packs and controllers areeasily portable. The risks of power line infection have been reduced by finer,more flexible electric cables, transcutaneous energy transmission or skull-mountedp edestals (74) . As an "off the shelf" commodity LVAD use could exceed transplantation by af actoro f5 0t o1 .T houghs urvival benefit was clearly showni nt he REMATCH study, quality of life was limited by LVAD-relatedcomplications (75) . Chronic infection caused4 1% of LVAD deaths and by two years the probability of LVAD mechanical failurew as 35%. Therew as a4 2% incidence of bleeding, complications by 6months and an overall stroke rate of 10%. Many of these problems wereinherent in the design and power supply of the first generation pulsatile bloodpump designed in the 1980s. During the course of REMATCH recruitment it was clear that early mortality occurred largely through failuret or esurrect moribund patients with multiorgan failure. With moresensible patient selection and initial 2-year survival of 21% improved to 43% late in the recruitment phase. by implanting beforeterminal decline and with improved postoperative management, the University of Utaha chieved 85% one-year and 65% two-year survival with the same device.
Refinement of LVAD technology has already improved outcomes.T he first patient to receive ap ermanent Jarvik Flowmaker in the UK remains active in the communityafter 7years of event-free survival (76) . Skull pedestal power delivery allows all external components(power line, batteries and controllers) to be exchanged, an important optioni nl ifetime support (74) (Fig. 6 ). Other rotary blood pumps including the ThermoCardiosystems II, berlin Incor, Ve ntracor and Terumo LVADs arei nc linical use and appear suitable for lifetime support (73) . Concernsthat pulse pressurei sr equired to maintain end organ function in the human have already been dispelled by both laboratory and clinical experience (77) . Mechanical reliability and resistance to infection areimpressive. In the first 150 Jarvik Flowmaker patientst hereh as been no blood pump malfunction. The remainingissue of thromboembolism has been addressed by device modifications and improved anticoagulant regimes.T hesen oiseless, easily portable andu serfriendly rotary blood pumps allow the patient to live an unrestricted and productive life including long haul air travel.
Analysis of mortality in LVAD patients show that many die from irreversible organ dysfunction already present at the time of device implantation (75) . Patients consideredfor lifetime LVAD use have by protocol been ineligible for cardiac transplantation and in an advanced state of decompensation. Many have multi-site pacing,animplantable defibrillator or are confined to hospitalwith intravenous inotropes or an intra-aortic balloon pump. As such they have been left too late. The REMATCH study outcomes indicated that when apatient is considered unsuitable for transplantation by the same argument they may already have an unreasonably high risk for LVAD surgery (75) . The decision to provide lifetimecirculatory support should be made on an elective basis not as a salvage procedure. With safer devices and less invasive operations, LVAD deployment should be brought forwardout of the end stage arena. given that circulatory support and rehabilitation have improved the results of cardiac transplantation, it is illogical and perhaps unethical to exclude potential transplant candidates from clinical trialso fL VA Dt herapy.S ome LVAD patients will inevitably requiretransplantation due to progressive right heart failure. Other individuals who have been excluded from transplantation through renal impairment or increased pulmonary vascular resistance, can improve sufficiently to regain transplant status.
Preliminary evidencesuggests that LVADs arecost effective by reducing hospitala dmissions and in some cases returning young patients to employment. Multi-site pacing and implantabled efibrillators are already widely accepted despite their limited symptomatic benefit. Bloodp umps provide better symptomatic relief and further clinical trails are needed to determine the survival benefit conferred by safer devices. The futurel ies with yet small pumps, which can be implanted withoutm ajor surgery in these high-risk patients. Whilst the economic implications of widespread LVAD use aresubstantial, other treatments for terminal illness already set the precedent. Hemodialysis is extensively used for maintenance treatmentofrenal failurepatients irrespective of age providing 60% two-year survival.
The native left ventricle supported by an LVAD has low systolic wall tension and increased endocardial blood flow.These conditions areideal to support cellular therapy formyocardial regeneration (78) .Whilst further discussion on the role of stem cell therapy is beyond the remit of this paper,i ti sr easonable to speculatethat the combination of LVAD with regenerative cell therapy may provide aw ay forwardf or many patientsw ith "inoperable" heart failure. One of the principle problems with cell transplantation is poor survival of the new cells. Most reports suggest that 70-90% of transplanted cells die within the first few days after introduction into the scarred myocardium (78) . Injected cells areexposed to an ischaemic environment with elevated wall tension. The more undifferentiated and ischaemia-resistant a cell is, the higher its engraftment rate will be. The mored ifferentiated ac ell is towards ac ardiac phenotype, the lower its resistance is, and the engraftment will be poor (79) . An ideal cell would be ischaemia-resistant initially and become fully functional after engraftment. Alternatively combinations of cells could be used to modify the local environment providing angiogenesis as well as myoblastc ontractilep otential. Multiple attempts have already been made to increase the angiogenic potentialofskeletal myoblasts by introducing the expression of the proangiogenic molecule vascular endothelial growth factor.C ombinations of angiogenicb one marrow and myogenic muscle derived cells arepromising (80) .
In summary,t he relationships between left ventricularshape, volume and prognosis have been clarified using modern imaging techniques and detailed follow up of heart failurepatientsafter surgery.L VEF is apoor prognostic measurebeforesurgery.L VEDP better reflects symptomatologyand outcome (81) . Of the three V's, vessel, valve and ventricle, reduction in left ventricular volume appearstoconvey most prognostic benefit. Clinical research supported by computer modelling has defined the benefits of VRS in both ischaemicand idiopathic dilated cardiomyopathies. However,whilst most surgeons have expertise in CAbg and mitral repair therea ppears to be considerably less understanding of volume reduction surgery particularly for IDCM. The use of circulatory support technology is expanding rapidly with improved safety of new devices.b oth short term and lifetime LVADs now play an important role in heart failures urgery.F or the future, the combination of mechanical left ventricular unloading together with myocardial tissue engineeringh olds great promise. These arespecialist areas, which cannot be adequately managed on an occasional basis. because of this, conventional (non-transplant)heart failuresurgery is now aspecialty in itself.
